[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"large-b-cell-lymphoma-lbcl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:large-b-cell-lymphoma-lbcl":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,48,74,104,127,152,180,205,226],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100556568","phase-2-surovatamig-azd0486-as-monotherapy-in-participants-with-relapsedrefractory-rr-b-cell-nhl-100556568",false,"NCT06526793","Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed\u002FRefractory (R\u002FR) B-cell NHL","A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R\u002FR) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)","SOUNDTRACK-B","1. Key Inclusion Criteria:\n\n   * Aged 18 years old and above\n   * Histologically confirmed relapsed refractory FL (Module 1) and LBCL (Module 2) after at least 2 prior lines of therapy\n   * ECOG performance status 0 to 2\n   * Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy\n   * FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined as \\> 1.5 cm in its longest dimension), or extranodal lesion (defined as \\> 1.0 cm in its longest dimension)\n   * Adequate hematological function: ANC ≥ 1000\u002Fmm3, platelets\n\n     * 75,000\u002Fmm3, hemoglobin ≥ 9 g\u002FdL. Transfusion and\u002For growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening\n   * Adequate liver function: total bilirubin \\\u003C1.5x ULN, AST\u002FALT ≤ 3xULN or \\\u003C 5 × ULN in the presence of lymphoma involvement of the liver\n   * Adequate renal function: creatinine clearance (CrCl) of ≥ 45 mL\u002Fmin\n   * Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram or MUGA\n\n   The above is a summary, other inclusion criteria details may apply.\n2. Key Exclusion Criteria:\n\n   * Diagnosis of CLL, Burkitt lymphoma, or Richter's transformation\n   * Active CNS involvement by B-NHL\n   * Leukemic presentation of B-NHL\n   * History of a clinically relevant CNS medical condition or pathology that required treatment in the preceding year, is currently symptomatic, or that the treating investigator considers to have the potential to interfere with the evaluation of safety, such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, neurodegenerative disorder including Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis or other severe mental illness.\n   * Prior therapy with T-cell engager (TCE) within 8 weeks, autologous Hematopoietic Stem Cell Transplantation (HSCT) within 12 weeks, CAR T- cell therapy within 6 months, or prior allogeneic HSCT within 24 weeks of first dose of surovatamig\n   * Requires chronic immunosuppressive therapy\n   * Unresolved non hematological AEs ≥ Grade 2 from prior therapies; history of ≥ Grade 3 CRS or neurotoxicity from prior CAR-T or TCE therapy\n   * History of major cardiac abnormalities.\n   * If female, participant must not be pregnant or breastfeeding.\n\nThe above is a summary, other exclusion criteria details may apply.","ALL","18 Years",{"count":20,"type":21},270,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed\u002Frefractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.",[27,28,29],"B-cell Non-Hodgkin Lymphoma","Follicular Lymphoma (FL)","Large B-Cell Lymphoma (LBCL)",[31,32,28,29,33,34],"AZD0486","Surovatamig","Non-Hodgkin lymphoma (NHL)","Relapsed\u002FRefractory","RECRUITING","2026-06-22",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":39},"2024-11-27",{"date":43,"type":21},"2032-10-21",{"name":45,"class":46},"AstraZeneca","INDUSTRY",94,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100641023","phase-2-ai-driven-treatment-strategy-vs-pola-r-chp-in-untreated-lbcl-100641023","NCT07594899","AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL","A Study to Evaluate the Efficacy and Safety of an AI-Driven Treatment Strategy Versus Pola-R-CHP in Patients With Previously Untreated Large B-Cell Lymphoma","GUIDANCE-10","Inclusion Criteria:\n\n* Age 18-75 years with comprehensive geriatric assessment stratified as fit\n* Previously untreated participants with CD20-positive LBCL (without central nervous system involvement)\n* ECOG Performance Status of 0, 1, or 2\n* After 1 cycle of Pola-R-CHP, classified as intermediate-risk or high-risk by AI-based multimodal stratification\n* Life expectancy ≥ 3 months\n* At least 1 measurable site of disease (defined as lymph nodes with the long diameters longer than 1.5cm, or extra-nodal sites with the long diameters longer than 1.0cm; meanwhile, any lesion site with at least 2 measurable vertical diameters)\n* The patient or his or her legal representative must provide written informed consent prior to any special examination or procedure for the research.\n* Anti-lymphoma drugs have not been used before (except glucocorticoids)\n\nExclusion Criteria:\n\n* Prior solid organ transplantation or SCT\n* Significant or extensive history of cardiovascular disease such as New York Heart Association Class III or IV cardiac disease or Objective Assessment Class C or D, myocardial infarction within the last 6 months prior to the start of Cycle 1, unstable arrhythmias, or unstable angina\n* History or presence of an abnormal ECG that is clinically significant in the investigator's opinion\n* Any of the following abnormal laboratory values (unless any of these abnormalities are due to underlying lymphoma):\n\n  * Absolute neutrophil count \\\u003C1.0 × 10⁹\u002FL.\n  * Platelet count \\\u003C75 × 10⁹\u002FL\n  * Serum AST and ALT ≥ 2.5 x ULN\n  * Total bilirubin ≥ 1.5 x ULN\n  * Serum creatinine clearance \\\u003C 30 mL\u002Fmin (using Cockcroft-Gault formula)\n* Any active infection within 7 days prior to Cycle 1 Day 1 that would impact participant safety\n* Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen \\[HBsAg\\] serology)：Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HbsAg) may be included if hepatitis B virus (HBV) DNA is undetectable at the time of screening. Such participants must be willing to undergo HBV DNA testing every month and appropriate antiviral therapy as indicated\n* Positive test results for hepatitis C (hepatitis C virus \\[HCV\\] antibody serology testing)：Participants positive for HCV antibody are eligible only if PCR is negative for HCV RNA\n* Participants with a history of progressive multifocal leukoencephalopathy\n* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 12 months after final dose of treatment\n* Participants with uncontrolled coagulation disorders, connective tissue diseases, severe infectious diseases\n* Other concurrent and uncontrolled medical conditions that, in the opinion of the investigator, would affect the patient's participation in the study","75 Years",{"count":58,"type":21},178,[24],"This is a prospective, open-label, multicenter, randomized controlled study in participants with previously untreated large B-cell lymphoma. Participants will be stratified into different risk groups using an AI-based multimodal model. Those classified as intermediate- or high-risk will be randomized in a 1:1 ratio to receive either an AI-guided treatment strategy or Pola-R-CHP. In the experimental arm, participants will receive either genotype-guided targeted agents in combination with Pola-R-CHP or Pola-R-CHP combined with glofitamab, according to their AI-defined risk group and molecular features. Participants in the control arm will receive Pola-R-CHP. The study will evaluate the efficacy and safety of the AI-guided treatment strategy compared with Pola-R-CHP.",[29],"NOT_YET_RECRUITING","2026-05-17",{"date":65,"type":39},"2026-05-19",{"date":67,"type":21},"2026-05-06",{"date":69,"type":21},"2029-12-31",{"name":71,"class":72},"Ruijin Hospital","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":103,"locationsCount":73},"100632475","phase-2-the-efficacy-and-safety-of-pola-zr-glo-in-older-treatment-naive-patients-with-lbcl-100632475","NCT07514169","The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL","The Efficacy and Safety of Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) Regimen in Older Treatment-naive Patients With Large B-cell Lymphoma (LBCL)","SILVERGLO","Inclusion Criteria:\n\nPatients must satisfy all of the following criteria to be enrolled in the study:\n\n* Histologically-confirmed large B-cell lymphoma (without central nervous system involvement)\n* Aged ≥ 70 years old with comprehensive geriatric assessment stratified as unfit or frail, or those who decline immunochemotherapy.\n* Eastern Cooperative Oncology Group Performance Status 0-2\n* At least 1 measurable site of disease (defined as lymph nodes with the long diameters longer than 1.5cm, or extra-nodal sites with the long diameters longer than 1.0cm; meanwhile, any lesion site with at least 2 measurable vertical diameters)\n* Life expectancy of at least 3 months determined by researchers\n* The patient or his or her legal representative must provide written informed consent prior to any special examination or procedure for the research.\n* Anti-lymphoma drugs have not been used before (except glucocorticoids)\n\nExclusion Criteria:\n\nPresence of any of the following criteria will exclude a patient from enrollment:\n\n* Uncontrolled blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases\n* Laboratory measures meet the following criteria at screening (unless caused by lymphoma):\n\nNeutrophils\\\u003C1.0×10\\^9\u002FL Platelets\\\u003C75×10\\^9\u002FL ALT or AST is 2.5 times higher than the upper limits of normal (ULN), serum bilirubin are 1.5 times higher than the ULN.\n\neGFR is lower than 30ml\u002Fmin\u002F1.73m\\^2 (according to Cockcroft-Gault Equation or MDRD Equation).\n\n* uncontrollable or significant cardiovascular diseases, including but not limited to: Left ventricular ejection fraction\\\u003C50% Cardiomyopathy, such as dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy QTc prolongation with clinical significance, QTc interval\\>470ms (females) or 480ms (males), type 2 second-degree atrioventricular block or third-degree atrioventricular block\n* Patients with HbsAg positive are required to have HBV DNA\\\u003C1.0×10\\^3 IU\u002Fml before entering the group. In addition, if the patient is HBsAg negative but HBcAb positive (regardless of HBsAb status), HBV DNA test is also required, and HBV DNA\\\u003C1.0×10\\^3 IU\u002Fml is required before entering the group\n* Patients with psychiatric disorders or patients who are known or suspected to be unable to fully comply with the study protocol\n* HIV-infected patients\n* History of stroke or intracranial hemorrhage within 6 months prior to start of therapy\n* Other medical conditions determined by the researchers that may affect the study","70 Years",{"count":84,"type":21},30,[24],"This is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen in older treatment-naive patients with large B-cell lymphoma.",[29],[89,90,91,92,93,94,95,96],"large B-cell lymphoma","polatuzumab vedotin","zanubrutinib","lenalidomide","glofitamab","older patients","unfit","frail","2026-05-05",{"date":99,"type":39},"2026-05-08",{"date":101,"type":39},"2026-03-31",{"date":69,"type":21},{"name":71,"class":72},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100636540","phase-2-emapalumab-prophylaxis-of-bispecific-t-cell-engagers-bites-associated-crs-and-icans-100636540","NCT07567014","Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS","A Phase II Study of the Interferon Gamma Inhibitor Emapalumab for Prophylaxis of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Lymphoma and Multiple Myeloma Receiving Bispecific T-Cell Engagers","Inclusion Criteria:\n\n1. Disease Criteria:\n\n   1. Adult patients (≥18 years) with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or that relapsed after first-line chemoimmunotherapy not eligible for high-dose therapy\u002Fautologous stem cell transplantation (HDT-ASCT) or Chimeric Antigen Receptor T- cell (CAR-T) therapy, or adult patients with relapsed\u002Frefractory (R\u002FR) LBCL after two or more lines of systemic therapy, who are planned to receive a commercially approved bispecific antibody therapy (e.g. epcoritamab, glofitamab). This includes:\n\n      * Diffuse large B-cell lymphoma (DLBCL) not otherwise specified,\n      * Primary mediastinal large B-cell lymphoma,\n      * High-grade B-cell lymphoma,\n      * DLBCL arising from follicular lymphoma.\n   2. Adult patients with R\u002FR multiple myeloma (MM) who have received multiple lines of therapy and are planned to receive a commercially approved bispecific antibody therapy. These prior therapies will typically include a proteasome inhibitor (e.g., bortezomib, carfilzomib), an immunomodulatory drug (e.g., lenalidomide, pomalidomide), and an anti-CD38 monoclonal antibody (e.g., daratumumab).\n2. Treatment Eligibility:\n\n   1. At least measurable disease per Lugano Criteria (for B-cell lymphomas) or per International Myeloma Working Group (IMWG) criteria (for multiple myeloma) at the time of screening.\n   2. At least 2 weeks or 5 half-lives (whichever is shorter) must have elapsed since any prior systemic therapy at the time the subject is planned for bispecific antibody therapy, except for systemic inhibitory\u002Fstimulatory immune checkpoint therapy. Steroids require only a 7-day washout.\n   3. At least 3 half-lives must have elapsed from any prior systemic inhibitory\u002Fstimulatory immune checkpoint molecule therapy (e.g., ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4-1BB agonists, etc.) before the planned bispecific therapy.\n3. Performance Status:\n\n   1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n4. Organ Function:\n\n   1. Adequate renal, hepatic, pulmonary, and cardiac function, defined as:\n   2. Absolute neutrophil count (ANC) ≥ 1000\u002FµL,\n   3. Platelet count ≥ 50,000\u002FµL,\n   4. Hgb \\> 7, and standard pre-medications are allowed per standard of care guidelines\n   5. Patients eligible to receive the bispecifics per institutional guidelines.\n   6. Absolute lymphocyte count ≥ 100\u002FµL\n   7. Creatinine clearance (as estimated by Cockcroft Gault or CKD-EPI) ≥ 30 mL\u002Fmin,\n   8. Serum ALT\u002FAST ≤ 2.5 times institutional upper limit of normal (ULN),\n   9. Total bilirubin ≤ 1.5 mg\u002FdL, except in subjects with Gilbert's syndrome,\n   10. Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ECG findings (current status)\n   11. Baseline oxygen saturation \\> 92% on room air.\n5. Reproductive Status:\n\n   1. Females of childbearing potential must have a negative serum or urine pregnancy test. Females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential.\n   2. Women of Childbearing Potential (WOCBP) must agree to use one highly effective method of contraception, including hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy or tubal ligation; and one effective method of contraception, including male condom, female condom, cervical cap, diaphragm or contraceptive sponge or abstain from heterosexual intercourse for the duration of study participation and for six months after the last bispecific antibody dose..\n   3. Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment.\n6. 6\\. Consent:\n\n   1. Ability to understand and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Other Malignancies:\n\n   a. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless disease-free for at least 2 years.\n\n   b. History of Richter's transformation of chronic lymphocytic leukemia (CLL).\n2. Stem Cell Transplantation:\n\n   1. Autologous stem cell transplant within 6 weeks of planned bispecific antibody therapy.\n   2. History of allogeneic stem cell transplantation within 6 months of planned bispecific antibody.\n3. Infections:\n\n   1. Presence of uncontrolled fungal, bacterial, viral, or other infections at the time of screening.\n   2. Patients with uncontrolled hepatitis B or C infection. Subjects with positive Hepatitis B or C serology should be started on appropriate antiviral therapy prior to Emapalumab infusion.\n   3. Patients must be negative for tuberculosis (TB). Subjects positive for latent tuberculosis prior to study must be started on or have completed with appropriate treatment prior to emapalumab infusion.\n   4. Patients must be negative for active cytomegalovirus (CMV, NAT), Epstein-Barr virus (EBV, NAT), and adenovirus (NAT) by PCR testing.\n4. Central nervous system (CNS) Disorders:\n\n   a. Evidence of active CNS disease, regardless of prior CNS history. b. History or presence of CNS disorder such as seizure disorder or cerebrovascular ischemia\u002Fhemorrhage within 6 months of enrollment.\n5. Cardiac and Pulmonary Events:\n\n   1. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 6 months of enrollment.\n   2. History of symptomatic pulmonary embolism within 3 months of enrollment (ongoing anticoagulation is allowed if beyond 3 months).\n6. Autoimmune Disease:\n\n   a. History of autoimmune disease requiring ongoing systemic immunosuppression. Steroids are allowed up to 5mg prednisone-equivalent for adrenal insufficiency.\n\n   b. Patients anticipated to require canakinumab, Janus kinase (JAK) inhibitors, Tumor necrosis factor (TNF) inhibitors, or tocilizumab for baseline autoimmune\u002Finflammatory disease at the time of bispecific antibody therapy initiation.\n7. Vaccination:\n\n   1. Receipt of a Bacillus Calmette-Guérin (BCG) vaccine within 12 weeks prior to screening.\n   2. Receipt of any live or attenuated live vaccine (other than BCG) within 4 weeks prior to screening.\n8. Investigational Agents:\n\n   a. Participants receiving any other investigational agents for their condition.\n9. Pregnancy or Breastfeeding:\n\n   a. Females who are pregnant or breastfeeding, or participants unwilling to use birth control during the study and for 6 months after bispecific therapy.\n10. Inability to Participate:\n\n    1. In the investigator's judgment, subjects unlikely to complete all protocol required study visits or procedures, including follow-up visits, or comply with study participation requirements.",{"count":112,"type":21},60,[24],"The purpose of this study is to evaluate emapalumab as a prophylactic therapy in preventing cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients with hematologic malignancies receiving bispecific antibodies (BsAbs) as outpatient. The primary objectives of this study are to evaluate the efficacy, safety, and feasibility of prophylaxis with the interferon gamma (IFN-У -γ) inhibitor Emapalumab in preventing CRS and\u002For ICANS in patients receiving bispecific antibody therapy for hematologic malignancies.",[116,117],"Multiple Myeloma","Large B-cell Lymphoma (LBCL)","2026-05-04",{"date":67,"type":39},{"date":121,"type":21},"2026-05-11",{"date":123,"type":21},"2029-05-31",{"name":125,"class":72},"NYU Langone Health",3,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":73},"100620715","phase-1-investigator-initiated-study-to-assess-the-safety-of-combination-of-cls-015-with-anti-cd-19-car-t-cells-in-patients-with-stableprogressive-large-b-cell-lymphoma-at-lymphodepletion-100620715","NCT07361224","Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable\u002FProgressive Large B Cell Lymphoma at Lymphodepletion.","CLS-015-TAMSC-LBCL-PR An Exploratory, Investigator Initiated Study to Assess the Safety of Combination of CLS-015 (DFF) With Anti-CD-19 CAR-T Cells in Patients With Stable\u002F Progressive Large B Cell Lymphoma at Lymphodepletion.","Inclusion Criteria:\n\n* Participant must be at least 18 years of age inclusive, at the time of signing the informed consent.\n* Large B-Cell lymphoma treated with CAR-T targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel)\n* Stable Disease or Progressive Disease confirmed by PET-CT on the day of lymphodepletion\n* Capable of giving signed informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\nExclusion Criteria:\n\n* Hypersensitivity to CLS-015\n* Evidence of any clinically significant condition, disorder, condition, or disease that, in the opinion of the Investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.\n* Active infection requiring antibiotics\n* Females only: Pregnant or breastfeeding",{"count":135,"type":21},12,[137],"PHASE1","This is a Phase 1, single-center, open-label study to evaluate the safety of CLS-015 in combination with anti-CD19 CAR-T therapy in patients with large B-cell lymphoma. The goal is to improve clinical response by reversing the negative effects of NETs on immune function and CAR-T cells.",[29],[141],"Large B-Cell lymphoma","2026-04-27",{"date":144,"type":39},"2026-05-01",{"date":146,"type":21},"2026-05",{"date":148,"type":21},"2028-02",{"name":150,"class":151},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":159,"enrollmentInfo":160,"targetDuration":162,"studyType":163,"phases":4,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":73},"100633294","real-world-practice-with-academic-anti-cd19-car-t-cell-therapy-in-relapserefractory-b-cell-lymphoma-100633294","NCT07524816","Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse\u002FRefractory B-cell Lymphoma","Treatment Method of Patients With Refractory and Relapsed CD-19 Positive Leukemia and Lymphoma Using Academic Anti-CD19 CAR-T Human Cells","Inclusion Criteria:\n\n* age ≥18 years,\n* relapsed or refractory LBCL,\n* confirmed CD19 expression in tumor tissue,\n* prior exposure to at least one line of anti-tumor therapy\n\nExclusion Criteria:\n\n* pregnancy,\n* active hepatitis B or C infection, HIV infection,\n* naïve T-lymphocyte count (CD3+CCR7+CD45RO-) ≤ 0,5%","80 Years",{"count":161,"type":21},76,"3 Months","OBSERVATIONAL","Chimeric antigen receptor (CAR) T-cell therapy has been the standard of care for relapsed\u002Frefractory large B-cell lymphomas (R\u002FR LBCLs) since 2018. However, high cost of commercial products limits their application in real-world clinical practice. Academic approach to manufacturing CAR-T cell products can reduce the costs and improve availability and affordability of this therapy option. The aim of the present study is assess the efficacy and safety of the use of academic CAR-T cell products in r\u002Fr LBCL patients.This prospective observational study with r\u002Fr LBCL patients treated in the NN Alexandrov National Cancer Centre of Belarus. The CAR-T cell product was manufactured using lentiviral vector encoding anti-CD19 CAR.",[29],[167,168,169,170],"academic CAR-T cell products","r\u002Fr large B-cell lymphomas","efficacy","safety","2026-04-09",{"date":173,"type":39},"2026-04-13",{"date":175,"type":39},"2021-06-01",{"date":177,"type":21},"2029-01-01",{"name":179,"class":151},"N.N. Alexandrov National Cancer Centre",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":73},"100413241","phase-2-cd19-car-t-therapy-for-patients-with-newly-diagnosed-high-risk-large-b-cell-lymphoma-100413241","NCT04661020","CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma","Clinical Trial for the Efficacy and Safety of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma","Inclusion Criteria:\n\n1. Age no less than 18, no gender limit;\n2. Newly diagnosed high-risk Large B-cell Lymphoma, which was defined by the following criteria: (1) DLBCL not otherwise specified with an IPI score ≥3 at diagnosis, (2) high grade B-cell lymphoma (HGBL) with gene rearrangement of MYC and BCL2 and\u002For BCL6, (3) HGBL not otherwise specified;\n3. Confirmed CD19 and CD20 postive expressions in lymphoma cells\n4. ECOG score 0-2;\n5. Total bilirubin ≤ 51 umol\u002FL, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol\u002FL;\n6. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;\n7. No active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%;\n8. Estimated survival time ≥ 3 months;\n9. Patients or their legal guardians volunteer to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Central nervous system involvement by lymphoma；History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases;\n2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;\n3. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);\n4. Active infection of hepatitis B virus or hepatitis C virus;\n5. Previously treated with any CAR-T cell product or other genetically modified T cell therapies;\n6. Insufficient amplification capacity in response to CD3\u002FCD28 co-stimulus signal (\\\u003C5 times) ;\n7. Other uncontrolled diseases that were not suitable for this trial;\n8. Patients with HIV infection;\n9. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.",{"count":188,"type":21},40,[24],"A Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma",[29],[193,194,195],"CD19","Large B-Cell Lymphoma","CAR-T","2026-04-01",{"date":198,"type":39},"2026-04-07",{"date":200,"type":39},"2020-12-03",{"date":202,"type":21},"2026-12-20",{"name":204,"class":72},"Zhejiang University",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100627368","phase-1-exploratory-clinical-study-on-the-safety-and-efficacy-of-cd19x-car-t-cell-injection-in-the-treatment-of-relapsedrefractory-large-b-cell-lymphoma-100627368","NCT07447726","Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed\u002FRefractory Large B-Cell Lymphoma","Inclusion Criteria:\n\n* 1\\. The participant has given consent and signed the informed consent form, and is willing and able to comply with planned visits, research treatments, laboratory tests, and other trial procedures;\n* 2\\. Clinically diagnosed with relapsed\u002Frefractory large B-cell lymphoma, and confirmed by pathology or flow cytometry that tumor cells express CD19, including: diffuse large B-cell lymphoma (DLBCL), transformed indolent B-cell lymphoma to DLBCL (excluding Richter transformation), and meeting the following criteria (satisfying one of the first two and the third): i. Relapse ≥6 months after achieving remission following first-line adequate therapy or ≥12 months after stem cell transplantation; ii. Patients who did not achieve remission after at least 2-4 cycles of first-line chemotherapy combined with high-risk factors (double-expressor lymphoma, double-hit lymphoma, TP53 gene mutation or deletion, IPI score ≥3), or disease progression during first-line therapy, or progression within 6 months after achieving remission from prior sufficient therapy, or relapse within 12 months after achieving remission from stem cell transplantation; iii. The participant has received the following treatments for LBCL after diagnosis:\n\n  * Anti-CD20 monoclonal antibody;\n  * Combination chemotherapy containing anthracyclines.\n* 3\\. Age 18 years and above, both male and female;\n* 4\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;\n* 5\\. Expected survival of more than 3 months from the date of signing the informed consent form;\n* 6\\. HGB ≥ 60 g\u002FL (blood transfusion allowed); LYM ≥ 0.3\\*10\\^9\u002FL;\n* 7\\. Liver and kidney function, as well as cardiopulmonary function, must meet the following requirements:\n\n  1. Creatinine ≤ 1.5×ULN;\n  2. Left ventricular ejection fraction ≥ 50%;\n  3. Blood oxygen saturation \\> 90%;\n  4. Total bilirubin ≤ 1.5×ULN; ALT and AST ≤ 2.5×ULN;\n* 8\\. Study participants planning pregnancy must agree to use contraception before enrollment in the study and for one year after CAR-T cell infusion; participants should notify the investigator immediately if they become pregnant or suspect they are pregnant.\n\nExclusion Criteria:\n\n* 1\\. Severe heart failure with left ventricular ejection fraction \\\u003C50%;\n* 2\\. History of severe pulmonary dysfunction;\n* 3\\. Concurrent progressive malignant tumors;\n* 4\\. Severe infections that cannot be effectively controlled;\n* 5\\. Severe autoimmune diseases or congenital immunodeficiency;\n* 6\\. History of CAR-T cell immunotherapy;\n* 7\\. Active hepatitis (hepatitis B virus DNA \\[HBV-DNA\\] or hepatitis C virus RNA \\[HCV-RNA\\] levels above the detection limit);\n* 8\\. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection;\n* 9\\. History of severe allergic reactions to biological products (including antibiotics);\n* 10\\. Allogeneic hematopoietic stem cell transplant patients who still have acute graft-versus-host disease (GvHD) one month after discontinuing immunosuppressive drugs.\n* 11\\. Women who are pregnant or breastfeeding, or planning to become pregnant within 12 months;\n* 12\\. Individuals with other serious physical or mental illnesses or abnormal laboratory test results that may increase the risk of participating in the study, interfere with the study results, or whom the researcher considers unsuitable for participation in this study.",{"count":126,"type":21},[137,24],"This study is an open-label, single-arm, prospective, exploratory clinical trial involving patients with relapsed\u002Frefractory large B-cell lymphoma, aiming to preliminarily assess the safety and efficacy of CAR-T cell infusion.",[29],[216],"relapsed\u002Frefractory","2026-02-26",{"date":219,"type":39},"2026-03-03",{"date":221,"type":21},"2026-04-05",{"date":223,"type":21},"2028-01-01",{"name":225,"class":72},"Institute of Hematology & Blood Diseases Hospital, China",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":234,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":73},"100613672","phase-1-golcadomide-poseltinib-and-rituximab-for-relapsedrefractory-diffuse-large-b-cell-lymphoma-100613672","NCT07269639","Golcadomide, Poseltinib, and Rituximab for Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma","Golcadomide, Poseltinib, and Rituximab for Optimized Treatment of Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma (Go-Pro-DLBCL)","Go-Pro-DLBCL","Inclusion Criteria:\n\n* Subjects must satisfy the following criteria to be enrolled in the study\n\n  1. Subject is ≥ 19 years of age at the time of signing the informed consent form (CRF).\n  2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments\u002Fprocedures being conducted.\n  3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.\n  4. Subject has histologically confirmed (per local evaluation) diagnosis of aggressive large B-cell lymphoma according to 2022 WHO classification, specifically:\n\n     A. DLBCL, NOS (including GCB and ABC types) B. DLBCL\u002Fhigh grade B-cell lymphoma, with MYC and BCL2 rearrangements C. High grade B-cell lymphoma, NOS D. T-cell\u002Fhistiocyte-rich large B-cell lymphoma E. EBV-positive DLBCL\n  5. Relapsed or refractory disease following at least 1 prior line of therapy (must include an anthracycline-based treatment), and ineligible for hematopoietic stem cell transplantation.\n  6. Subjects must have measurable disease defined by at least one fluorodeoxyglucose (FDG)-avid lesion for FDG-avid subtype and one bi-dimensionally measurable (\\> 1.5 cm in longer diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification.\n  7. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n  8. Subject must have the following laboratory values:\n\n     A. ANC ≥ 1.0 × 109\u002FL or ≥ 0.5 × 109\u002FL in case of documented bone marrow involvement of DLBCL-related hypersplenism present. It is not permissible to administer G-CSF to achieve minimum ANC levels within 7 days prior to screening complete blood count (or within 14 days prior for pegfilgrastim).\n\n     B. Hemoglobin ≥ 75 g\u002FL (7.5 g\u002FdL). Transfusion is permitted in cases of bone marrow involvement of lymphoma, and screening will be conducted at least one week after transfusion.\n\n     C. Platelets ≥ 75 × 109\u002FL or ≥ 50 × 109\u002FL in case of documented bone marrow involvement of DLBCL-related hypersplenism present, without transfusion for 7 days.\n\n     D. AST and ALT ≤ 2.5 × ULN. In case of documented liver involvement by lymphoma, AST and ALT must be ≤ 5.0 × ULN.\n\n     E. Serum total bilirubin ≤ 1.5 × ULN (corresponding to mild dysfunction as per National Cancer Institute Organ Dysfunction Working Group \\[NCI ODWG\\] criteria). In case of documented liver involvement by lymphoma, serum total bilirubin must be ≤ 3.0 × ULN.\n\n     F. Estimated serum CrCL of ≥ 30 mL\u002Fmin using the modification of diet in renal disease (MDRD) formula G. International normalized ratio (INR) \\\u003C 1.5 × ULN and activated partial thromboplastin time (aPTT) \\\u003C 1.5 × ULN (for subjects not receiving therapy). Note: subjects receiving therapy for a thromboembolic event that occurred \\> 3 months prior to enrollment are eligible as long as they are on a stable regimen of anticoagulation with warfarin, low-molecular weight heparin, or other approved therapeutic anticoagulation or antiplatelet regimen.\n  9. Individual of childbearing potential (IOCBP) must:\n\n     A. Have two negative pregnancy tests as verified by the investigator prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after the end of study treatment. This applies even if the subject practices true abstinence\\* from heterosexual contact.\n\n     B. Either commit to true abstinence\\* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, 2 forms of contraception: one highly effective, and one additional effective (barrier) measure of contraception without interruption 28 days prior to starting study treatment, during the study treatment (including dose interruptions), and for at least 28 days after the last dose of golcadomide, and for 12 months after the last dose of rituximab and poseltinib, whichever is longer.\n\n     Note: IOCBP is an individual who: 1) has achieved menarche (first menstrual cycle) at some point; 2) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral salpingectomy (the surgical removal of the fallopian tubes) or oophorectomy (the surgical removal of both ovaries) or 3) has not been naturally postmenopausal (without an alternative medical cause, e.g. amenorrhea following cancer therapy does not rule out childbearing potential) for at least 12 consecutive months (ie, has had menses at any time during the preceding 12 consecutive months).\n  10. Female subjects must agree to refrain from donating eggs while on study treatment and for at least 28 days after last dose of golcadomide.\n  11. Male subjects must:\n\n      A. Practice true abstinence\\* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant individual or an IOCBP while participating in the study, during dose interruptions, and for at least 28 days after the last dose of golcadomide or 90 days for rituximab or 12 months for poseltinib, whichever is longer, even if he has undergone a successful vasectomy.\n\n      B. Agree to refrain from donating sperm or semen while on study treatment, during dose interruptions and for at least 12 months after last dose of study treatment.\n\n      \\* True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. \\[Periodic abstinence (e.g., calendar, ovulation, post-ovulation methods) and withdrawal are not acceptable methods of contraception\\].\n  12. Subjects must:\n\nA. Agree to refrain from donating blood while on study treatment, during dose interruptions and for at least 28 days following the last dose of golcadomide.\n\nB. Agree to refrain from receiving live vaccines while on study treatment, during dose interruptions and for at least 90 days following the last dose of the study treatment.\n\nC. Agree not to share study medication with another person.\n\nExclusion Criteria:\n\n* The presence of any of the following will exclude a subject from enrollment:\n\n  1. Subject who has had prior treatment with golcadomide.\n  2. Subject who has had prior treatment with BTK inhibitor.\n  3. Subject has life expectancy ≤ 2 months.\n  4. Subject has received any of the following:\n\n     A. Major surgery (as defined by the Investigator) within 28 days of initiating study treatment. Subjects must have recovered from any clinically significant effects of recent surgery.\n\n     B. Radiation therapy within 28 days prior to initiating study treatment. C. Use of any systemic anti-cancer treatment (approved or investigational) within 28 days or 5 half-lives prior to starting study treatment, whichever is shorter. (Participation in another interventional clinical trial concurrent with this study is not permitted, except for those who have completed treatment with the prior investigational agent(s) and are currently in long-term follow up)\n  5. Subject has previously received solid organ transplantation.\n  6. Subject has undergone allogeneic SCT within 1 year prior to initiating study treatment or autologous SCT within 3 months prior to initiating study treatment.\n\n     A. Subject who had received prior SCT should not have any Grade \\>1 treatment-related toxicity.\n\n     B. Subject who had received prior SCT should not have clinically significant, active graft-versus-host disease (GVHD).\n  7. Subject has any other subtype of lymphoma. Cases of primary mediastinal (thymic) large B-cell lymphoma, primary cutaneous DLBCL-leg type, Grade 3b FL, ALK-positive large B-cell lymphoma, primary effusion lymphoma, or Burkitt lymphoma are excluded.\n  8. Subject has active central nervous system (CNS) involvement by lymphoma\n  9. Subject has any significant medical condition (e.g., uncontrolled diabetes mellitus, uncontrolled hypertension), including active or uncontrolled infection, presence of laboratory abnormality, or psychiatric illness that places the subject at an unacceptable risk for treatment-related complications, if he\u002Fshe were to participate in the study.\n  10. Subject has any condition that confounds the ability to interpret data from the study.\n  11. Persistent diarrhea or malabsorption grade ≥ 2 NCI CTCAE, despite medical management. Subject with gastrointestinal disease or surgery (e.g., gastric bypass surgery) that may significantly alter the absorption of oral study treatment.\n  12. Subject has a prior history of malignancies other than lymphoma, except if the participant has been free of the disease for at least 3 years. Exceptions to the ≥ 3-year time limit include history of the following:\n\n      A. Localized nonmelanoma skin cancer B. Carcinoma in situ of the cervix C. Carcinoma in situ of the breast D. Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor Node Metastasis staging system) or prostate cancer that has been treated with curative intent\n  13. Subject has impaired cardiac function or clinically significant cardiovascular disease, defined as any of the following within 6 months prior to enrollment:\n\n      A. Acute myocardial infarction or acute coronary syndromes (e.g., unstable angina, coronary artery bypass graft, coronary angioplasty or stenting, symptomatic pericardial effusion) B. Clinically significant cardiac arrhythmias (e.g., uncontrolled atrial fibrillation, uncontrolled paroxysmal supraventricular tachycardia, persistent ventricular arrhythmias) C. Prolonged QT syndrome (or QTcF ≥ 470 msec on screening electrocardiogram) D. Left ventricular ejection fraction (LVEF) \\\u003C 45% as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO) E. Complete left bundle branch or bifascicular block\n  14. Concurrent administration of strong CYP3A4\u002F5 modulators. The washout period for strong CYP3A4\u002F5 modulators is 7 days or 5 half-lives (whichever is longer) before initiation of golcadomide.\n  15. Subject is unable or unwilling to undergo protocol required thromboembolism or antiviral prophylaxis.\n  16. Subject is positive for human immunodeficiency virus (HIV), chronic or active hepatitis B, active hepatitis A, or active hepatitis C:\n\n      A. Known positive HIV status B. Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen \\[HBsAg\\] either acute or chronic hepatitis). Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen \\[anti-HBcAb\\] and\u002For antibodies to hepatitis B surface antigen \\[anti-HBsAb\\]) must be screened using real-time polymerase chain reaction (PCR) measurement of HBV deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded. HBV carriers without active disease (HBV DNA titer \\\u003C 1000 copies\u002FmL or 200 IU\u002FmL) may be enrolled in the study with adequate anti-viral prophylaxis.\n\n      EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.\n\n      EXCEPTION: Subjects with positive anti-HBcAb but negative HBsAg and negative anti-HBsAb profiles are eligible if HBV DNA PCR is negative.\n\n      C. Known to be seropositive for hepatitis C virus (HCV); anti-HCV antibody positive and HCV- ribonucleic acid (RNA) quantitation positive. Cured HCV patients (negative for HCV RNA test) may be enrolled in the study.\n  17. Subject hast a history of anaphylaxis or hypersensitivity to investigational products or components of investigational products (rituximab, golcadomide, poseltinib).\n  18. Subject is an individual who is pregnant, nursing, or breastfeeding, or who intends to become pregnant during participation in the study.","19 Years",{"count":236,"type":21},20,[137,24],"This trial is a proof-of-concept, pilot study, phase I\u002FII clinical trial aimed at generating preliminary data on the combination of golcadomide, poseltinib, and rituximab.",[29],[241,242,243,244],"large b-cell lymphoma","golcadomide","poseltinib","rituximab","2025-11-25",{"date":247,"type":39},"2025-12-08",{"date":249,"type":21},"2026-01-01",{"date":251,"type":21},"2028-09-01",{"name":253,"class":72},"Seoul National University Hospital"]